{
    "clinical_study": {
        "@rank": "117912", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who\n      have stage IVB or recurrent cervical cancer."
        }, 
        "brief_title": "Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer", 
        "completion_date": {
            "#text": "May 2001", 
            "@type": "Actual"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene in patients with stage\n      IVB or recurrent cervical carcinoma. II. Determine the safety of this drug in this patient\n      population.\n\n      OUTLINE: Patients receive 6-hydroxymethylacylfulvene IV over 5 minutes daily for 5\n      consecutive days. Treatment continues every 28 days in the absence of unacceptable toxicity\n      or disease progression.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed primary metastatic (stage IVB) or\n        recurrent cervical carcinoma not amenable to curative therapy Squamous Adenocarcinoma\n        Adenosquamous Bidimensionally measurable disease No active brain metastases\n\n        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life\n        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3\n        Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal ALT/AST no greater than 2.5\n        times upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN (1.95\n        mg/dL at MSKCC) OR Creatinine clearance at least 50 mL/min Cardiovascular: No New York\n        Heart Association class III or IV congestive heart failure No ECG evidence of acute\n        ischemia No significant conduction abnormality (e.g., bifascicular block, 2nd or 3rd\n        degree AV blocks) Other: Not pregnant or nursing Negative pregnancy test Fertile patients\n        must use effective contraception No other malignancy within the past 5 years and deemed\n        low risk for recurrence No other concurrent clinical circumstances that would compromise\n        safety or integrity of trial\n\n        PRIOR CONCURRENT THERAPY: Prior multimodality therapy at diagnosis allowed (i.e.,\n        concurrent chemotherapy and radiotherapy, neoadjuvant chemotherapy followed by surgery\n        and/or radiotherapy, adjuvant chemotherapy and/or radiotherapy following surgery, or\n        adjuvant chemotherapy following radiotherapy) Biologic therapy: Not specified\n        Chemotherapy: No prior chemotherapy for metastatic or recurrent disease Endocrine therapy:\n        Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 4\n        weeks since prior major surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "April 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005070", 
            "org_study_id": "99-072", 
            "secondary_id": [
                "CDR0000067675", 
                "NCI-T99-0096"
            ]
        }, 
        "intervention": {
            "intervention_name": "irofulven", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Irofulven"
        }, 
        "keyword": [
            "recurrent cervical cancer", 
            "stage IVB cervical cancer", 
            "cervical squamous cell carcinoma", 
            "cervical adenocarcinoma", 
            "cervical adenosquamous cell carcinoma"
        ], 
        "lastchanged_date": "June 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-99072"
        }, 
        "official_title": "A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Carol Aghajanian, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005070"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {}
}